Bristol Myers Squibb (CELG-RI) Income towards Parent Company (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Income towards Parent Company of $2.7 billion for Q1 2026, up 8.81% YoY from $2.5 billion in Q1 2025, and up 146.69% sequentially from $1.1 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Income towards Parent Company (2009 - 2026) Analysis & Trends
Bristol Myers Squibb has disclosed Income towards Parent Company across 18 years of filings, most recently posting $2.7 billion for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 8.81% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $7.3 billion (up 197.81% YoY), while the FY2025 annual figure was $7.1 billion, up 178.99% from the prior year.
- Income towards Parent Company advanced to $2.7 billion in Q1 2026, from $1.1 billion in the prior quarter.
- Over the last five years, Income towards Parent Company for CELG-RI reached as high as $2.7 billion in Q1 2026 and fell as low as -$11.9 billion in Q1 2024.
- The 5-year median for Income towards Parent Company is $1.6 billion (2024), against an average of $883.5 million.
- Annual changes were most pronounced in 2024 — Income towards Parent Company tumbled 625.28% — and 2025, when it soared 1328.95%.
- A 5-year view of Income towards Parent Company shows it stood at $2.0 billion in 2022, then fell by 15.7% to $1.7 billion in 2023, then slumped by 95.55% to $76.0 million in 2024, then soared by 1328.95% to $1.1 billion in 2025, then soared by 146.69% to $2.7 billion in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered $2.7 billion, $1.1 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.68 Bn |
| Dec 31, 2025 | 1.09 Bn |
| Sep 30, 2025 | 2.20 Bn |
| Jun 30, 2025 | 1.31 Bn |
| Mar 31, 2025 | 2.46 Bn |
| Dec 31, 2024 | 76.00 Mn |
| Sep 30, 2024 | 1.16 Bn |
| Jun 30, 2024 | 1.63 Bn |
| Mar 31, 2024 | -11.91 Bn |
| Dec 31, 2023 | 1.71 Bn |
| Sep 30, 2023 | 1.93 Bn |
| Jun 30, 2023 | 2.08 Bn |
| Mar 31, 2023 | 2.27 Bn |
| Dec 31, 2022 | 2.03 Bn |
| Sep 30, 2022 | 1.61 Bn |
| Jun 30, 2022 | 1.43 Bn |
| Mar 31, 2022 | 1.28 Bn |
| Dec 31, 2021 | 2.37 Bn |
| Sep 30, 2021 | 1.48 Bn |
| Jun 30, 2021 | 995.00 Mn |